ValueQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMSelling/general/admin expenses2.04 M2.23 M2.06 M3 M2.44 M3.42 M10.92 MResearch & development2.97 M3.2 M3.11 M6.36 M1.88 M43.65 K11.39 MOperating income-5 M-5.43 M-5.17 M-9.36 M-4.32 M-6.95 M-25.79 MNon-Operating Income, Total159.6 K82.18 K79.7 K78.43 K73.65 K580.28 K812.05 KInterest expense, net of interest capitalized-28——————Non-Operating Income, excl. Interest Expenses79.81 K82.18 K00000Unusual income/expense79.81 K—79.7 K78.43 K73.65 K580.28 K812.05 KPretax income-4.85 M-5.34 M-5.09 M-9.28 M-22.39 M-6.37 M-43.13 MEquity in earnings———————Taxes—0002 0003392 339Non-controlling/minority interest———————After tax other income/expense———————Net income before discontinued operations-3.57 M-4.52 M-5.35 M-8.9 M-3.63 M-6.37 M-24.25 MDiscontinued operations———————Net income-3.57 M-4.52 M-5.35 M-8.9 M-3.63 M-6.37 M-24.25 MDilution adjustment———————Preferred dividends———————Diluted net income available to common stockholders-3.57 M-4.52 M-5.35 M-8.9 M-3.63 M-6.37 M-24.25 MBasic earnings per share (Basic EPS)-0.08-0.16-0.18-0.27-0.09-0.14-0.68Diluted earnings per share (Diluted EPS)-0.08-0.16-0.18-0.27-0.09-0.14-0.68Average basic shares outstanding22.2 M27.7 M30.3 M33.2 M32.11 M45.21 M—Diluted shares outstanding22.2 M27.7 M30.3 M33.2 M32.11 M45.21 M—EBITDA———————EBIT———————Cost of revenue———————Other cost of goods sold———————Depreciation & amortization (cash flow)———————
MAIA Biotechnology, Inc. Common Stock
MAIA Biotechnology, Inc. is a public, immune-oncology company based in Chicago, IL focused on the development of telomere targeting agents for the treatment of telomerase-positive cancer cells.